Debiopharm Group has regained all rights to Alisporivir, a cyclophilin
inhibitor being investigated for the treatment of hepatitis C virus
infection, as a result of a new agreement between the pharmaceutical
company and Novartis, according to a news release from the company.
Alisporivir (DEB025, Debiopharm) is currently undergoing two phase 2 clinical trials of therapy without interferon for HCV, and has already been tested in over 2,000 patients, according to the release.
The release stated that Debiopharm and Novartis entered into a
partnership for the development of alisporivir in January 2010, which
allowed for the current transfer of ongoing alisporivir phase 2 clinical
trials to Debiopharm. The new agreement also transfers all rights for
HCV and other indications for the drug.
Labels: Alisporivir, Cyclophilin Inhibitor, Debiopharm, Novartis, phase 2